More real-world evidence bolsters role of bezlotoxumab in recurrent C. difficile infection
06 Nov 2020
byJairia Dela Cruz
Bezlotoxumab proves to be effective at thwarting the return of Clostridium difficile infection in high-risk populations, namely individuals with one or more risk factors for recurrence and patients who are immunocompromised, within 90 days and up to 24 weeks after initial infusion, respectively, according to two studies reported at the 2020 virtual IDWeek meeting.